Envafolimab

Generic Name
Envafolimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2102192-68-5
Unique Ingredient Identifier
ES1M06M6QH
Indication

用于不可切除或转移性微卫星高度不稳定(MSI-H)或错配修复基因缺陷型(dMMR)的成人晚期实体瘤患者的治疗,包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。

Associated Conditions
-
Associated Therapies
-

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Phase 2
Conditions
Interventions
First Posted Date
2022-04-19
Last Posted Date
2022-04-19
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
36
Registration Number
NCT05335460

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

First Posted Date
2022-03-28
Last Posted Date
2022-03-28
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Target Recruit Count
20
Registration Number
NCT05298020
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

First Posted Date
2022-02-14
Last Posted Date
2024-01-05
Lead Sponsor
Liangjun Zhu M.M.
Target Recruit Count
38
Registration Number
NCT05237349
Locations
🇨🇳

Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)

First Posted Date
2022-01-31
Last Posted Date
2024-01-29
Lead Sponsor
Sir Run Run Shaw Hospital
Target Recruit Count
32
Registration Number
NCT05216653
Locations
🇨🇳

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients

First Posted Date
2022-01-28
Last Posted Date
2023-06-13
Lead Sponsor
Zhejiang University
Target Recruit Count
39
Registration Number
NCT05213221
Locations
🇨🇳

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-01-24
Last Posted Date
2023-06-22
Lead Sponsor
The First People's Hospital of Lianyungang
Target Recruit Count
40
Registration Number
NCT05203276
Locations
🇨🇳

The First People'S Hospital of Lainyungang, Lianyungang, Jiangsu, China

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

First Posted Date
2021-11-09
Last Posted Date
2024-11-29
Lead Sponsor
3D Medicines (Sichuan) Co., Ltd.
Target Recruit Count
108
Registration Number
NCT05112991
Locations
🇨🇳

Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

and more 16 locations

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Phase 2
Completed
Conditions
Interventions
First Posted Date
2021-10-05
Last Posted Date
2024-08-07
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
34
Registration Number
NCT05068427
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China

and more 9 locations

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-09-24
Last Posted Date
2021-09-24
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Target Recruit Count
20
Registration Number
NCT05055167
Locations
🇨🇳

First affiliated Hospital of Xiamen University, Xiamen, Fujian, China

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2021-05-18
Last Posted Date
2024-08-23
Lead Sponsor
3D Medicines (Sichuan) Co., Ltd.
Target Recruit Count
126
Registration Number
NCT04891198
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath